Anti-TCF3 / E2A antibody [7H3],Abcam,AB243152
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Want a custom formulation? This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact [email protected]
Host
Rat
Reactivity
Rat, Mouse
Application
WB, IHC-P
Platform ID
BAB238984526

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition (PubMed : 15226298, PubMed : 18214987). Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation (PubMed : 18214987). Together with TCF15, required for the mesenchymal to epithelial transition (PubMed : 11309385, PubMed : 15226298). Dimers bind DNA on E-box motifs : 5'-CANNTG-3' (PubMed : 15226298, PubMed : 18214987, PubMed : 30426815). Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer (By similarity). Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region (PubMed : 2181401).. Isoform E47. Facilitates ATOH7 binding to DNA at the consensus sequence 5'-CAGGTG-3', and positively regulates transcriptional activity. See full target information Tcf3
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.
